These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11140570)
1. Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Kucheryanu VG; Kryzhanovskii GN Bull Exp Biol Med; 2000 Jul; 130(7):629-32. PubMed ID: 11140570 [TBL] [Abstract][Full Text] [Related]
2. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597 [TBL] [Abstract][Full Text] [Related]
3. Recent insights into the mode of action of memantine and ketamine. Johnson JW; Glasgow NG; Povysheva NV Curr Opin Pharmacol; 2015 Feb; 20():54-63. PubMed ID: 25462293 [TBL] [Abstract][Full Text] [Related]
5. Functional interaction between N-methyl-D-aspartate receptor and ascorbic acid during neuropathic pain induced by chronic constriction injury of the sciatic nerve. Saffarpour S; Nasirinezhad F J Basic Clin Physiol Pharmacol; 2017 Nov; 28(6):601-608. PubMed ID: 28902622 [TBL] [Abstract][Full Text] [Related]
6. Glutamatergic drugs in Parkinson's disease. Lange KW; Riederer P Life Sci; 1994; 55(25-26):2067-75. PubMed ID: 7997066 [TBL] [Abstract][Full Text] [Related]
7. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Papa SM; Chase TN Ann Neurol; 1996 May; 39(5):574-8. PubMed ID: 8619541 [TBL] [Abstract][Full Text] [Related]
8. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment. He L; Di Monte DA; Langston JW; Quik M Neuroscience; 2000; 99(4):697-704. PubMed ID: 10974432 [TBL] [Abstract][Full Text] [Related]
9. Protection from glutamate-induced excitotoxicity by memantine. Kutzing MK; Luo V; Firestein BL Ann Biomed Eng; 2012 May; 40(5):1170-81. PubMed ID: 22203191 [TBL] [Abstract][Full Text] [Related]
10. Bis(7)-tacrine prevents glutamate-induced excitotoxicity more potently than memantine by selectively inhibiting NMDA receptors. Liu YW; Li CY; Luo JL; Li WM; Fu HJ; Lao YZ; Liu LJ; Pang YP; Chang DC; Li ZW; Peoples RW; Ai YX; Han YF Biochem Biophys Res Commun; 2008 May; 369(4):1007-11. PubMed ID: 18328812 [TBL] [Abstract][Full Text] [Related]
11. Alterations of plasma and cerebrospinal fluid glutamate levels in rats treated with the N-methyl-D-aspartate receptor antagonist, ketamine. Tomiya M; Fukushima T; Kawai J; Aoyama C; Mitsuhashi S; Santa T; Imai K; Toyo'oka T Biomed Chromatogr; 2006; 20(6-7):628-33. PubMed ID: 16779778 [TBL] [Abstract][Full Text] [Related]
12. Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the spinal neuronal responses to distension of the rat urinary bladder. Castroman PJ; Ness TJ Anesthesiology; 2002 Jun; 96(6):1410-9. PubMed ID: 12170054 [TBL] [Abstract][Full Text] [Related]
13. Ketamine, an N-methyl-D-aspartate receptor antagonist, inhibits the reflex responses to distension of the rat urinary bladder. Castroman PJ; Ness TJ Anesthesiology; 2002 Jun; 96(6):1401-9. PubMed ID: 12170053 [TBL] [Abstract][Full Text] [Related]
14. Neuropeptide Y release from cultured hippocampal neurons: stimulation by glutamate acting at N-methyl-D-aspartate and AMPA receptors. Gemignani A; Marchese S; Fontana G; Raiteri M Neuroscience; 1997 Nov; 81(1):23-31. PubMed ID: 9300398 [TBL] [Abstract][Full Text] [Related]
15. [Effects of substance P on experimental parkinsonian syndrome]. Kryzhanovskiĭ GN; Atadzhanov MA; Kucherianu VG Biull Eksp Biol Med; 1989 Oct; 108(10):404-7. PubMed ID: 2480824 [TBL] [Abstract][Full Text] [Related]
16. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Alam M; Danysz W; Schmidt WJ; Dekundy A Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571 [TBL] [Abstract][Full Text] [Related]
17. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of memantine. Johnson JW; Kotermanski SE Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Kozela E; Pilc A; Popik P Psychopharmacology (Berl); 2003 Jan; 165(3):245-51. PubMed ID: 12442203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]